Litcius/Paper detail

Macrotrabecular-Massive Hepatocellular Carcinoma: What Should We Know?

Xiaoming Li, Qiandong Yao, Chen Liu, Jian Wang, Huarong Zhang, Shiguang Li, Ping Cai

2022Journal of Hepatocellular Carcinoma19 citationsDOIOpen Access PDF

Abstract

Hepatocellular carcinoma is one of the most common malignancies globally. Recently, a newly identified histological subtype, designated as "macrotrabecular-massive hepatocellular carcinoma" (MTM-HCC), has been associated with an aggressive phenotype and has received extensive attention. MTM-HCC was a strong independent prognostic predictor of early and overall recurrence because it is closely related to tumor molecular subclass, gene mutation, carcinogenesis pathways, and immunohistochemical markers. In addition, preoperative imaging examination can potentially provide an essential clue for diagnosing MTM-HCC, intratumor necrosis or ischemia is an independent predictor for MTM-HCC on Gd-EOB-DTPA enhanced MRI or CT. Early diagnosis and appropriate treatment of MTM-HCC could prove beneficial for preventing early recurrence and could improve outcomes.

Topics & Concepts

Hepatocellular carcinomaMedicineImmunohistochemistryPhenotypeCarcinomaCarcinogenesisOncologyPathologyInternal medicineCancerGeneBiologyBiochemistryHepatocellular Carcinoma Treatment and PrognosisHepatitis B Virus StudiesCancer, Lipids, and Metabolism
Macrotrabecular-Massive Hepatocellular Carcinoma: What Should We Know? | Litcius